Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 2Central Nervous System Neoplasms 2Oligodendroglioma 1Gliosarcoma 1Cognition Disorders 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 16Radiotherapy 11Lomustine 8Carmustine 6Vincristine 5Procarbazine 5Etoposide 3Corticotropin-Releasing Hormone 3Carboplatin 3vorasidenib 2Thiotepa 2Radiotherapy, Intensity-Modulated 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Isotretinoin 2Everolimus 2Dihematoporphyrin Ether 2Cisplatin 2Chemotherapy, Adjuvant 2etoposide phosphate 1carmustine, poliferprosan 20 drug combination 1Valproic Acid 1Tranexamic Acid 1Trabedersen 1Thioguanine 1Surgical Procedures, Operative 1Semustine 1Radiotherapy, Conformal 1Radiosurgery 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Astrocytoma × DNA Methylation × Clear all
NCT00626990 2023-09-11

CATNON

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Active not recruiting
751 enrolled 18 charts
CNS

Astrocytoma, Oligodendroglioma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡